Cutar sankarau ta COVID-19 ta kawo mana tarin karairayi da shedar shedar haske wadanda basu da niyya don sanar da Amurkawa fiye da karfafa iko da siyan lokaci. Daga cikin waɗannan akwai sanannen canjin Anthony Fauci daga jayayya game da sanya abin rufe fuska, zuwa ba da shawarar sanya ɗaya, kuma, a ƙarshe, zuwa saka biyu.
Fauci ya kuma yi ƙoƙarin gamsar da mu cewa ba a sarrafa kwayar cutar ta SARS-CoV-2 a cikin dakin gwaje-gwaje ba duk da cewa da'irar sa ta yi masa imel game da "sabon abu fasali" na kwayar cutar da ta yi kama da "mai yiwuwa sarrafawa. " Kuma, ba shakka, muna da "kwanaki goma sha biyar don dakatar da yaɗuwar," ra'ayi mara kyau wanda ya ci gaba har tsawon shekaru biyu. Don kada masu karatu su yi mana laifi don mantawa, akwai kuma rigimar “samar da aiki”, yaƙin kariyar da aka mayar da hankali, rufe makarantu, kulle-kulle, umarnin alluran rigakafi, da kuma ɓarnatar da alluran rigakafi.
Wadannan batutuwa sun sami kulawar jama'a sosai. Babban batun cutar da ba shi da shi, kuma yana da mahimmanci, shine ivermectin mara kyau. Lokaci yayi da za a saita rikodin madaidaiciya.
Idan kun bi labarin sosai a cikin shekaru biyu da suka gabata, tabbas kun ji wasu abubuwa game da ivermectin. Na farko, cewa maganin dabbobi ne da aka yi niyya don dawakai da shanu. Na biyu, cewa FDA da sauran hukumomin gwamnati sun ba da shawarar hana amfani da shi don COVID-19. Na uku, cewa hatta mai ƙirƙira kuma mai yin ivermectin, Merck & Co., ya fito gaba da shi. Na hudu, cewa ɗayan manyan binciken da ke nuna cewa ivermectin ya yi aiki don COVID-19 an janye shi don zamba. Kuma, a ƙarshe, cewa mafi girma kuma mafi kyawun bincike na ivermectin, gwaji tare, ya nuna cewa ivermectin bai yi aiki ba.
Bari mu yi la'akari da shaida.
Ivermectin yana da tarihin ban mamaki, kuma yana iya kasancewa amfanin kwatankwacin na penicillin. Binciken rigakafin cutar ya haifar da lambar yabo ta Nobel da kuma biliyoyin gwamnatoci masu aminci a duniya, hatta tsakanin yara da mata masu juna biyu. "Ivermectin yana samuwa ko'ina a duniya, mara tsada, kuma ɗaya daga cikin magunguna mafi aminci a ciki magungunan zamani. "
FDA ta ba da gargaɗi na musamman game da amfani da ivermectin don COVID-19. FDA ta gargadi, wanda ya haɗa da harshe irin su, "launi mai tsanani," "a asibiti," "mai haɗari," "mai hatsarin gaske," "kamuwa," "komawa har ma da mutuwa," da "mai guba," na iya ba da shawarar cewa FDA ta kasance. gargadi a kan kwayoyin da aka lika da guba, ba magani da FDA ta riga ta amince da shi ba. Me yasa ya zama haɗari lokacin amfani da COVID-19? FDA ba ta ce ba.
Saboda dokokin FDA, idan za a yi wani bayani akan ivermectin, ya kasance wajabta a kai masa hari. FDA ta hana haɓaka magunguna don amfanin da ba a yarda da su ba. Tunda yaƙar SARS-CoV-2 ya kasance rashin yarda da amfani da ivermectin, FDA ba za ta iya ba da shawarar amfani da ita ba tare da munafunci ba. Mai gano Ivermectin, Merck & Co., yana da dalilai da yawa don ɓata magungunan nasa.
Merck, kuma, ba zai iya samun "inganta" ivermectin bisa doka ba don COVID-19 ba tare da cikakkiyar amincewar FDA ba, wani abu da zai ɗauki shekaru da miliyoyin daloli. Bugu da ƙari, Merck ba ya samun kuɗi da yawa daga arha, generic ivermectin amma yana fatan samun nasara tare da sabon magani mai tsada, Lagevrio (molnupiravir).
Babban binciken ivermectin don COVID-19 ta Elgazzar et al. an janye ne bisa zargin satar bayanan karya da karya. Yawancin rahotannin kafofin watsa labaru sun yi kama da wannan binciken mai ban mamaki, amma yana ɗaya daga cikin yawancin nazarin asibiti. Bayan an cire karatun da aka cire daga la'akari, akwai gwaji 15 waɗanda bayar da shawarar da cewa ivermectin ba ya aiki ga COVID-19 da 78 waɗanda ke yi.
Gwajin TOGETHER ya sami babban latsawa mai inganci. The New York Times ya ruwaito masana biyu da suka ga sakamakon. Daya ya ce, "Hakika babu alamar wata fa'ida [daga ivermectin]," yayin da ɗayan ya ce, "A wani lokaci zai zama ɓarna na albarkatu don ci gaba da nazarin hanyar da ba ta dace ba."
Yayin da aka yi watsi da takardar Elgazzar da sauri, an yaba da gwajin TARE. Bai kamata ya kasance ba. Masu binciken da suka yi nazari sun gano matsalolin 31 masu mahimmanci (bayanan da ba za a iya yiwuwa ba; matsanancin rikice-rikice na sha'awa; rashin cin nasara makanta), 22 matsaloli masu tsanani (sakamako sun jinkirta watanni shida, bayanan rikice-rikice), da 21 manyan matsalolin (masu yawa, ka'idojin bazuwar bazuwar) tare da shi.
Duk da yake sanannen labari shine cewa gwaji na TOGETHER ya nuna cewa ivermectin bai yi aiki ga COVID-19 ba, ainihin sakamakon ya ƙaryata cewa ƙarshe: ivermectin yana da alaƙa da ƙananan haɗarin mutuwa na kashi 12, kashi 23 cikin 17 ƙananan haɗarin iskar injin, kashi 10 cikin 26 ƙananan haɗarin asibiti, da kashi 91 cikin XNUMX ƙananan haɗarin tsawaita asibiti ko lura da ER. Mun ƙididdige cewa yuwuwar ivermectin ya taimaka wa marasa lafiya a cikin gwajin TOGETHER ya kasance daga kashi XNUMX na matsakaicin adadin kwanakin zuwa farfadowa na asibiti zuwa kashi XNUMX don hana asibiti. Yakamata a bayar da rahoton sakamakon TGETHER daidai.
Dangane da shaidar asibiti daga gwaje-gwajen 93 da ke ivermectin rage mace-mace da matsakaicin kashi 51, da kuma a kan kiyasta yawan mace-macen kamuwa da cutar COVID-19, Kimanin Amurkawa 400 da suka kamu da cutar masu shekaru 60-69 za su bukaci a yi musu magani da ivermectin don a kididdigar hana mutuwa guda a cikin wannan rukunin. Jimlar farashin ivermectin don hana wannan mutuwa ɗaya: $40,000. (Bisa kan gidan yanar gizon GoodRx, ana siyar da takardar sayan magani na ivermectin a kusan $40. Za a buƙaci kusan 2.5 takardun magani ga kowane mutum don karɓar matsakaicin kashi na 150 MG kowace haƙuri.)
Nawa ne darajar rayuwar ku? Muna yin fare yana da daraja fiye da $40,000.
Lokacin da annoba ta gaba ta kama, ta larura za mu dogara ga tsofaffin magunguna saboda sababbi suna buƙatar shekaru na haɓaka. Ivermectin magani ne da aka sake dawowa wanda ke taimakawa, kuma zai iya taimakawa sosai. Ya cancanci a gane, ba wulaƙanci ba. Abin da muke bukata, duk da haka, ita ce hanyar da za mu bijiro da kanmu daga karya da kuma batanci na manyan mutane, kungiyoyi, da kamfanonin magunguna. Abin baƙin ciki, babu irin waɗannan alluran rigakafin cutar.
-
David R. Henderson abokin bincike ne a Jami'ar Stanford Hoover Institution, kuma farfesa a fannin tattalin arziki a Makarantar Digiri na Kasuwanci da Manufofin Jama'a, Makarantar Naval Postgraduate School, a Monterey, California.
Duba dukkan posts
-
Charles L. Hooper shine shugaban kasa kuma wanda ya kafa Objective Insights, Inc. Kafin kafa Maƙasudin Insights a 1994, Charley yayi aiki a Merck & Co., Syntex Labs, da NASA. Kwarewar Charley tana cikin nazarin yanke shawara, tattalin arziki, farashin samfur, hasashen hasashen, da ƙirar ƙira. Yana da sha'awar taimaka wa kamfanonin harhada magunguna suyi tunani a sarari game da damar kasuwancin su.
Duba dukkan posts
